摘要
目的总结溶质载体家族3成员2(solute carrier family 3 member A2,SLC3A2)基因在肝细胞癌发生和发展过程中的作用及相关机制,归纳并寻找该基因在肝细胞癌患者诊断、治疗、预后等方面的临床运用前景和价值。方法收集并整理近年来国内外SLC3A2基因及它与肝细胞癌相关研究的文献并进行综述与总结。结果SLC3A2在肝细胞癌中的表达明显高于正常肝组织,它主要通过调节细胞内外氨基酸的转运、抑制细胞发生铁死亡、激活雷帕霉素的机制靶点蛋白复合体信号途径及整合素信号途径而影响肝细胞癌的进展,并在患者的诊断、治疗及预后方面发挥重要作用。结论从本综述收集的文献总结结果提示,SLC3A2与肝细胞癌的迁移、侵袭、增殖和细胞凋亡密切相关,有望作为评判肝细胞癌患者生存期和预后的指标,并有可能成为未来肝细胞癌有效治疗的靶点之一。
Objective To summarize the possible roles and relevant mechanisms of solute carrier family 3 member A2(SLC3A2)gene in hepatocellular carcinoma(HCC),and explore its clinical application prospects and value in the diagnosis,treatment,and prognosis of patients with HCC.Method The literature on reseaches of the SLC3A2 gene and its association with HCC both domestically and internationally in recent years was reviewed and summarized.Results Notably,the SLC3A2 exhibited obviously elevated expression in the HCC tissue as compared with the normal liver tissue.It mainly affected the disease progression of HCC by regulating the intracellular and extracellular amino acids transport,inhibiting the ferroptosis of cells,activating the mechanistic target of rapamycin complex signaling pathways and integrin signaling pathway,and played an important role in the diagnosis,treatment,and prognosis of patients with HCC.Conclusion From the results of literature review collected,SLC3A2 might be closely associated with the migration,invasion,proliferation,and apoptosis of HCC cell,and it is expected to serve as an indicator for evaluating survival and prognosis of patients with HCC,and become one of the effective treatment targets for HCC in future.
作者
喻国涛
陈刚
尹燕锋
颜春涛
马丽
朱家顺
胡宗强
YU Guotao;CHEN Gang;YIN Yanfeng;YAN Chuntao;MA Li;ZHU Jiashun;HU Zongqiang(Department of Hepatobiliary Pancreatic Surgery,Kunming First People’s Hospital,Kunming 650011,P.R.China)
出处
《中国普外基础与临床杂志》
CAS
2023年第10期1265-1272,共8页
Chinese Journal of Bases and Clinics In General Surgery
基金
国家自然科学基金(项目编号:82060436)
云南省科学技术厅(项目编号:202205AC160089)
云南省科学技术厅(项目编号:202302AA310018)
昆明医科大学研究生创新基金(项目编号:2023S397)。
关键词
溶质载体家族3成员2
肝细胞癌
作用机制
靶向治疗
solute carrier family 3 member A2
hepatocellular carcinoma
action mechanism
targeted therapy